Back to compounds

COMPOUND PROFILE / PEPTIDES & ANALOGUES

Avorelin.

Research draft

Avorelin is a long-acting GnRH agonist investigated in prostate cancer, not a growth-hormone-releasing peptide.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

Avorelin is a long-acting GnRH agonist investigated in prostate cancer, not a growth-hormone-releasing peptide.

CLASSIFICATIONPeptides & analogues
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

Prolonged stimulation of GnRH receptors suppresses gonadotropin and testosterone responses after an initial phase.

Human research

Depot research demonstrated hormone suppression in patients with prostate cancer.

Preclinical & other research

Primate endocrine work examined effects of testosterone suppression.

Safety & unknowns

Hormonal suppression has substantial reproductive and metabolic implications; it is not a wellness GH booster.

Regulatory status

Investigational evidence must be matched to the avorelin depot formulation.

Reported use & evidence

Research profile draft

The supplied Avorelin profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds